A role for maintenance therapy in managing sarcoma.
Cancer treatment reviews • Vol. 38, Issue 5 • 2012
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Molecular cancer therapeutics • Vol. 10, Issue 6 • 2011
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 26, Issue 3 • 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 14, Issue 9 • 2008
